Pentobarbital will lessen the extent or impact of lumacaftor/ivacaftor by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Stay away from; coadministration with CYP3A inducers may end in diminished plasma concentrations of elvitegravir and/or possibly a concomitantly administered protease inhibitor and bring about loss of therapeutic influence and to possible ... https://janisn407wxy6.ziblogs.com/profile